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Case report
   40-year-old male initially presented to a community hos-
pital with a 20-lb weight loss over a few months. In retro-
spect, the patient recalled mild left-flank discomfort and 
fatigue, but denied any hematuria. Blood work revealed an 
elevated serum glucose, and he was diagnosed with type 2 
diabetes. Further workup included ultrasound, which re-
vealed a tumor in his retroperitoneum abutting a left moi-
ety of  a horseshoe kidney.
The patient’s past medical history was significant for re-
cently diagnosed type 2 diabetes and a knee ligamentous 
injury at the age of  14. Medications included metformin, 
diamicron, ventolin, and symbicort. His family history con-
sisted of  a maternal grandfather requiring a nephrectomy; 
the patient was unsure of  the cause. There was no known 
family history of  renal-cell carcinoma. 
Physical examination was unremarkable, with no flank or 
abdominal pain. All biochemical and hematological 
workup was normal, including CBC, LFTs, creatinine, and 
calcium. 
Imaging findings
CT of  the abdomen and pelvis, done in the portal ve-
nous phase, demonstrated a solid, hypodense, 4.5-cm renal 
mass containing calcifications, located in the posterior as-
pect of  the medial 
portion of  the left 
renal moiety of  
the horseshoe 
kidney (Fig. 1). 
The mass did not 
enhance strongly 
in the venous 
phase, and there 
was no apparent 
metastatic dis-
ease. Subsequent 
MRI attempted 
to further charac-
terize the renal 
mass; it revealed 
an enhancing left 
renal upper pole 
mass measuring 
approximately 
4.1 x 3.8 cm, 
which demon-
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Carcinoid tumor is the classic famous anonym of  neuroendocrine neoplasms. Primary renal carcinoid 
tumors are extremely rare, first described by Resnick and colleagues in 1966, with fewer than a total of  
100 cases reported in the literature. Thus, given the paucity of  cases, the clinical and histological behav-
ior is not well understood, impairing the ability to predict prognosis. Computed tomography and (occa-
sionally) octreotide studies are used in the diagnosis and followup of  these rare entites. A review of  85 
cases in the literature shows that no distinctive imaging features differentiate them from other primary 
renal masses. The lesions tend to demonstrate a hypodense appearance and do not usually enhance in 
the arterial phases, but can occasionally calcify. Octreotide scans do not seem to help in the diagnosis; 
however, they are more commonly used in the postoperative followup. In addition, we report a new case 
of  primary renal carcinoid in a horseshoe kidney.
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Figure 1. Computed tomography imaging of axial slices, unen-
hanced (A) and enhanced (B), showing left renal carcinoid (circled 
in red) in horseshoe kidney. 
strated a heterogeneous signal intensity on both T1 and 
T2-weighted images with areas of  bright signal on T1-
weighted images, likely due to intralesional hemorrhage 
(Fig. 2). Although the tumor abutted the psoas muscle, it did 
not appear to invade it.
Management
A pre-operative chest radiograph was negative for meta-
static disease. The patient was taken to the operating room 
and underwent an uncomplicated partial left nephrectomy. 
Intra-operatively, it was obvious that the mass did not in-
vade the psoas muscle. Pathology revealed a well-
differentiated neuroendocrine tumor, its histology compati-
ble with carcinoid. Numerous immunostains were per-
formed. The neoplastic cells were negative for inhibin, 
TTF-1, keratin 903, carbonic anhydrase IX, PAX-2, RCC 
antigen, S-100, CD10, CK7, and CK20. The tumor cells 
were strongly and diffusely positive for neuroendocrine 
markers, including synaptophysin, chromogranin A, and 
CD56. The cells were also positive for vimentin and weakly 
for racemase (AMACR). The proliferation index, as dem-
onstrated by Ki-67 staining, was low, at 1-2%. 
Followup
Postoperative CT thorax, octreotide study, endoscopy, 
and colonoscopy were all negative, with no source of  gas-
trointestinal tumor identified. The patient is now approxi-
mately two years post surgery, with no evidence of  local 
recurrence or metastatic disease. 
Discussion
Etiology and demographics 
Carcinoid tumor is the classic famous anonym of  neuro-
endocrine neoplasms, first described in 1888 by Lubarsch 
(1). It gained its name from the earlier description of  be-
nign behavior of  the lesion despite its malignant appear-
ance under microscopy (2). It arises from a wide variety of  
tissues and organs, most commonly from specialized endo-
crine cells in the gastrointestinal and respiratory tracts, with 
prevalence values of  66.9% and 24.5%, respectively (3). 
The tumors produce hormones and protein products asso-
ciated with specific clinical symptoms, and their malignant 
potential varies by location and cell type. Primary renal 
carcinoid tumors are extremely rare; they were first de-
scribed by Resnick and colleagues in 1966 (4), with fewer 
than a total of  100 cases reported in the literature (5, 6). 
Thus, given the paucity of  cases, the clinical and histologi-
cal behavior is not well understood, impairing the ability to 
predict prognosis. 
Carcinoid tumors arise from neuroendocrine cells and 
are believed to originate from enterochromafin or amine 
precursors and decarboxylation cells with malignant poten-
tial; however, neuroendocrine cells are not identified in the 
kidney or renal pelvis (7-10). Although renal carcinoid tu-
mors exhibit morphologic and immunohistochemical fea-
tures consistent with a hindgut neuroendocrine phenotype, 
the precise pathogenesis is controversial (11). Several hy-
potheses have been proposed, on the basis that these tu-
mors arise from interspersed neuroendocrine cells associ-
ated with acquired and/or congenital abnormalities. The 
first hypothesis suggests that chronic inflammation induces 
metaplasia of  the pyelocalciceal urothelium (12-14). The 
second suggests that they are metastases from an unknown 
primary (15). The third is that the neural crest or pancre-
atic cells have been misplaced or abnormally migrated dur-
ing embryogenesis (14, 16). The fourth suggests concurrent 
congenital renal abnormalities (17, 18). And the last hy-
pothesis suggests activation of  gene sequences in multipo-
tent primitive stem cells (5, 19, 20-28).
Methods
We performed an extensive literature search for all re-
ported renal primary carcinoid tumors. In total, we re-
viewed 85 cases, with one unpublished case from our insti-
tution. We evaluated demographical, clinical, histopa-
thological, and prognostic data, with a focus on radiologic 
findings. 
Demographics
Of  the 85 cases, 50 were males (59%) and 35 females 
(41%), with ages ranging from 12 to 75. The average age of 
diagnosis was 47.7 years, and the median age was 49 years. 
Forty-eight tumors were right-sided, and 37 were left-sided. 
Of  the 85 cases, 50 were between 0-4 cm, 34 cases were 
more than 4 cm, and one size was not specified. 
Several cases in the literature have reported coexisting 
renal anomalies such as horseshoe kidney and teratomas, 
suggesting that this disease may perhaps be more common 
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Figure 2. MRI 
axial T1 Dixon 
VIBE out of phase 
(A), T1 VIBE 
gadolinium-
enhanced fat-
saturated (B), and 
T1 FLASH 
gadolinium-
enhanced fat-
saturated se-
quences (C) 
showing left renal 
mass (circled in 
yellow) in a 
horsehoe kidney.
when there are predisposing embryological factors (17, 5). 
Of  the 85 cases, 19 were in horseshoe kidneys (22.3%) and 
10 in teratomas (11.8%). Of  those not in horseshoe kid-
neys, 51 of  66 cases were in the renal parenchyma (77.3%), 
3 were in the renal pelvis (4.5%), 3 in the renal hilum 
(4.5%), and 8 were not specified. 
Presentation
Patients with carcinoid tumors usually present with non-
specific symptoms related to the mass such as pain, obstruc-
tion, a palpable abnormality, or hematuria. Rarely are 
symptoms related to hormone production and result in 
carcinoid syndrome, first described in 1957 by Pernow and 
Waldenstrom (29), and characterized by skin flushing and 
telangiectasia, diarrhea, abdominal pain, cardiac valvular 
lesions, and bronchoconstriction. Carcinoid syndrome was 
found in only 4 of  the 85 cases. 
These tumors are often discovered incidentally, as in 26 
of  the cases. Thirty-nine patients presented with metastatic 
disease: 28 with metastases in lymph nodes, 8 in bones, 3 in 
lungs, 1 in the renal bed, 1 in the bowel, 1 in the spleen, 1 
in the thyroid, and 1 in the breast. 
Diagnosis
Initial evaluation often includes biochemical testing with 
urinary 5-HIAA, tumor localization with CT, and pre- or 
post-operative octreotide scans. Diagnostic workup prac-
tices were extremely varied in the cases analyzed, likely 
since the tumor is rare and there is no standard, or com-
mon, practice. 
Urinary 5HIAA 
The measurement of  serotonin metabolite 5-HIAA in 
24-hour urine collection has been historically used to con-
firm the diagnosis and subsequently to monitor patients 
with metastatic carcinoid tumors (30). It was only occasion-
ally ordered in the renal carcinoid cases reviewed. Urinary 
5-HIAA is not considered sensitive or specific for carcinoid 
syndrome, as it may be elevated in other conditions such as 
tropical sprue, celiac disease, Whipple’s disease, and small 
bowel obstructions (31).
Octreotide scintigraphy
Octreotide scintigraphy has been introduced into the 
radiological armamentarium as a sensitive imaging modal-
ity for the diagnosis and staging of  carcinoid tumors, par-
ticularly gastrointestinal carcinoid. Radioactive octreotide is 
a synthetic and slowly degraded somatostatin analog that 
binds to somatostatin receptors. Of  the primary carcinoids 
and metastases of  gastrointestinal and bronchial origin, 
more than 85% have high-affinity receptors for somatosta-
tin (32, 33). Thus, the reported sensitivity of  this method in 
detecting carcinoid tumors has been reported to be greater 
than 85% (32, 34, 35). 
Nevertheless, it is not routinely used in the renal carci-
noid pre-operative workup. More commonly, although still 
not performed often, the octreotide scan is used for post-
resection monitoring (32). In fewer than 10 cases in the 
literature were octreotide studies performed, 60% of  which 
were 1 to 2 months after surgical resection (and were 
negative). 
Thus, given the paucity of  cases, octreotide sensitivity is 
not well established. Although it has a high stated sensitiv-
ity in detecting gastrointestinal tumors, relatively little is 
known about renal carcinoids such as the somatostatin re-
ceptor prevalence. Further, a known limitation of  scintig-
raphy with octreotide to evaluate primary kidney carcinoids 
is that the normal renal uptake of  tracer material may ob-
scure a suspicious lesion (36).
CT is most often used for postoperative surveillance, but 
it occasionally lacks the accuracy needed for postoperative 
staging and monitoring. Long-term followup is suggested, 
as new metastases have been reported as long as 7 years 
after resection (6). Thus, the octreotide scan could poten-
tially serve as an adjunct for staging and surveillance of  
metastatic disease. 
Radiologic imaging findings
Of  the 85 cases, only 29% were hyperdense; the remain-
ders were either hypodense (55%) or not specified (15%). 
Of  the enhanced cases, only 18% demonstrated marked 
enhancement, and 14% showed mild enhancement. Calci-
fications were a common feature in one third of  the cases.
Differential diagnosis 
Thus, no specific radiologic feature on CT or MRI de-
fines renal carcinoid, making the differentiation between 
renal carcinoid and renal-cell carcinoma unreliable on im-
aging alone (37). These stated radiological findings are 
most commonly seen with renal-cell carcinoma, and fea-
tures should prompt consideration of  renal-carcinoid tu-
mors in the differential diagnosis, especially in the presence 
of  the rare hormone-producing syndromes. 
Pathology
Renal carcinoids typically exhibit the classic features of  
carcinoids found in other sites (38). They are well demar-
cated from adjacent normal parenchyma. Microscopically, 
cells are round or polygonal and are characterized by 
tightly packed cords and trabeculae of  neoplastic cells ap-
pearing eosinophilic with a granular cytoplasm (38, 39). 
Trebecular/gyriform, insular, glandular, solid, and mixed 
architectural patterns are seen. Nuclei are round and con-
tain fine stippled chromatin (39). They have a ribbonlike 
appearance, with minimal stroma (often composed of  fi-
brous tissue). Calcifications are present in around 25% of  
cases, and frequent mitosis (42 per 10 HPFs) are character-
istically absent (39). Microscopic foci of  necrosis and focal 
areas of  cytologic atypia are not uncommon (38). 
The ability to diagnose these tumors has greatly in-
creased since the advent of  immunohistochemical staining. 
Carcinoid tumors stain positive for cytokeratin, chromo-
granin, synaptophysin, gremileus, and neuron-specific eno-
lase, which serve to distinguish these tumors from renal-cell 
carcinoma (5, 40).
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